Prosecution Insights
Last updated: November 04, 2026

Freeline Therapeutics Limited

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Freeline Therapeutics Limited is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The data indicates that this prosecution activity is limited to 1 distinct examiner and 1 distinct art unit. This suggests a targeted approach to the company's current patent filings with all active matters residing in a single technical division.

The busiest examiner for the portfolio is BOWERS, ERIN M, who is assigned 1 busiest examiner pending office action. As there is only 1 distinct examiner listed for the entire portfolio, BOWERS, ERIN M is handling all of the company's current pending actions. This means the company's immediate patent outcomes are tied to the specific examination style of this individual.

The presence of 1 distinct art unit confirms that the technical subject matter is being reviewed within a single specialized group. With 1 pending office action in total, the portfolio's current activity is centralized. Practitioners can focus their attention on the requirements of the 1 distinct examiner to resolve the company's current pending matters.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BOWERS, ERIN M 1 54.7% +9.8%

Top Art Units

Art UnitApps
1653 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17795767 IMPROVED ASSAY FOR DETERMINING NEUTRALISING ANTIBODY TITRE TO A VIRAL VECTOR BOWERS, ERIN M 1653 §103 Final Rejection — Pending Jul 27, 2022

Managing Freeline Therapeutics Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Freeline Therapeutics Limited have?

Freeline Therapeutics Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Freeline Therapeutics Limited applications?

Erin M Bowers has the most, with 1 of Freeline Therapeutics Limited's pending office actions.

What technology area are Freeline Therapeutics Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month